© Springer-Verlag Berlin Heidelberg 2015Dédée F. Murrell (ed.)Blistering Diseases10.1007/978-3-662-45698-9_55 55. Management of Bullous Pemphigoid Mae N. Ramirez-Quizon1 , Luca Borradori2 , Russell P. HallIII3 and Dédée F. Murrell4 (1) Department of Dermatology, St George Hospital, Sydney, NSW, Australia (2) Department of Dermatology, University…
Pregnancy categorya First line: Topical corticosteroids C Systemic corticosteroids C Others: Tetracyclines D Nicotinamide D Cyclophosphamide D Cyclosporin C Azathioprine D Dapsone C IVIg C Rituximab C Plasmapheresis Unclassified…
© Springer-Verlag Berlin Heidelberg 2015Dédée F. Murrell (ed.)Blistering Diseases10.1007/978-3-662-45698-9_54 54. The Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus Jaehwan Kim1 , Benjamin S. Daniel2 , Victoria P. Werth3 , Pascal Joly4 and Dédée F. Murrell5 (1) Laboratory for Investigative Dermatology, The Rockefeller University, New York,…
4. Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg. 2009;6(1):13–9.CrossRefPubMedCentralPubMed 5. Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Investig…
Fig. 51.1 Pharmacology of cyclophosphamide. Cyclophosphamide is metabolised by the hepatic cytochrome P450 enzymes including CYP3A4 and CYP2B6 to form the active metabolite 4-hydroxy-cyclophosphamide. As the active hydroxylated cyclophosphamide is…
© Springer-Verlag Berlin Heidelberg 2015Dédée F. Murrell (ed.)Blistering Diseases10.1007/978-3-662-45698-9_48 48. Mycophenolate Mofetil for the Management of Autoimmune Bullous Diseases Marina Eskin-Schwartz1 and Daniel Mimouni2 (1) Department of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel…
50. Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita-successful treatment of colchicine. Arch Dermatol Res. 1994;286(1):35–46.CrossRefPubMed 51. Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad…
Steroid used Converting to Prednisone/prednisolonea Oral dexamethasone IV dexamethasone Intravenous hydrocortisone Topical betamethasone valerate (0.1%)b Topical clobetasol propionate (0.05 %)b Converting from Prednisone/prednisolonea Multiply by 1 mg/kg/day Multiply by 0.12…
Fig. 43.1 Clinical features of Kindler syndrome. (a) Poikiloderma present on the neck of this 28-year-old individual harbouring the compound heterozygous mutations, p.Glu304X and p.Leu302X, in the FERMT1 gene. (b)…
Fig. 38.1 Conjunctival papule characteristic of JEB LOC syndrome (courtesy of Prof. Minas Coroneo) 38.4 Management of LOC Syndrome There is no consensus regarding the optimal treatment of LOC, and…
